KOD

Kodiak Sciences Inc

87.63

Oct 23 • 3:59 PM ET +1.85 (2.16%)

87.50

Aftermarket • 7:36 PM ET -0.13 (-0.15%)

Healthcare Biotechnology USA Mid NASD

Peers: OCUL EYPT FDMT REGN BLTE RGNX OTLK OCGN ROIV HROW

| Held by: VTI XBI IWM VXF IBB IWO VTWO SCHA FESM DFAS

Scroll to Statements

Index	RUT
Market Cap	5.51B
Enterprise Value	5.53B
Income	-241.99M
Sales	0.00M
Book/sh	0.97
Cash/sh	2.00
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	124
IPO	Oct 04, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	90.12
P/C	43.75
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	2.49
Current Ratio	2.49
Debt/Eq	2.50
LT Debt/Eq	2.34
Option/Short	Yes / Yes

EPS (ttm)	-4.19
EPS next Y	-3.85
EPS next Q	-1.06
EPS this Y	5.58%
EPS next Y	5.61%
EPS next 5Y	50.98%
EPS past 3/5Y	12.22% -8.23%
Sales past 3/5Y	- -
EPS Y/Y TTM	-10.60%
Sales Y/Y TTM	-
EPS Q/Q	-1.85%
Sales Q/Q	-
Earnings	Aug 13 AMC
EPS/Sales Surpr.	-9.78% -

Insider Own	8.55%
Insider Trans	53.89%
Inst Own	102.97%
Inst Trans	4.94%
ROA	-94.25%
ROE	-368.37%
ROIC	-118.60%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-4.30%
SMA50	50.49%
SMA200	116.90%
Trades

Shs Outstand	62.83M
Shs Float	57.48M
Short Float	16.31%
Short Ratio	5.63
Short Interest	9.38M
52W High	104.00 -15.74%
52W Low	15.83 453.45%
Volatility	6.83% 10.82%
ATR (14)	6.91
RSI (14)	59.18
Beta	2.03
Rel Volume	0.32
Avg Volume	1.66M
Volume	526,753

Perf Week	2.19%
Perf Month	163.79%
Perf Quarter	109.09%
Perf Half Y	95.43%
Perf YTD	213.41%
Perf Year	412.16%
Perf 3Y	5517.31%
Perf 5Y	-24.46%
Perf 10Y	-
Recom	1.33
Target Price	121.67
Prev Close	85.78
Price	87.63
Change %	2.16%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-24-26	Resumed	Goldman	Neutral	$36
May-11-26	Upgrade	Chardan Capital Markets	Neutral → Buy	$61
Nov-11-25	Upgrade	H.C. Wainwright	Neutral → Buy	$24
Oct-24-25	Upgrade	JP Morgan	Neutral → Overweight	$24
Sep-25-25	Upgrade	Barclays	Underweight → Equal Weight	$17
Sep-22-25	Initiated	Jefferies	Buy	$15
Aug-14-25	Upgrade	JP Morgan	Underweight → Neutral	$15
Dec-09-24	Upgrade	Jefferies	Hold → Buy	$20
Sep-05-24	Initiated	H.C. Wainwright	Neutral	$3
Dec-11-23	Resumed	Goldman	Sell	$2
Nov-17-23	Upgrade	CapitalOne	Equal Weight → Overweight	$7 → $12
Jul-27-23	Downgrade	UBS	Buy → Neutral	$15 → $4
Jul-25-23	Downgrade	JP Morgan	Neutral → Underweight
Jul-25-23	Downgrade	Chardan Capital Markets	Buy → Neutral
Jul-24-23	Downgrade	Jefferies	Buy → Hold
Jul-24-23	Downgrade	CapitalOne	Overweight → Equal Weight	$7
Nov-15-22	Initiated	CapitalOne	Overweight	$24
Aug-02-22	Downgrade	Citigroup	Neutral → Sell	$6
Feb-24-22	Downgrade	JP Morgan	Overweight → Neutral	$90 → $21
Feb-11-22	Initiated	Goldman	Buy	$70

Show Previous Ratings

Oct-07-26 07:00AM	Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026 (PR Newswire)
Oct-02-26 11:00AM	This week in charts: Kodiaks big comeback and Hengruis dealmaking (BioPharma Dive)
Sep-29-26 05:24PM	This is the top biotech stock pick from B Riley Securities (Investing.com)
12:23AM	Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs? (Stocktwits)
12:01AM	New Eye Treatment Boosts Kodiak Into Ranks of Resurgent Biotechs (The Daily Upside)
10:13PM	Loading…
Sep-28-26 10:13PM	KOD Stock Cracks Septembers Top 5 Biotech Gainers On Eye Drug Win But Pharma Bro Shkreli Says It Still Sucks (Stocktwits) +177.96%
04:14PM	Why This Regeneron Eye Rival Just Catapulted More Than 170% (Investor's Business Daily)
01:35PM	Under the Radar: Kodiak Shares Surge as Eye Drug Matches Regeneron's (The Wall Street Journal)
01:04PM	Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial (Proactive)
12:11PM	Kodiak skyrockets on positive study data for 2 eye drugs (BioPharma Dive)
12:09PM	Kodiaks stock rallies on Phase III wAMD success (Clinical Trials Arena)
11:21AM	Kodiak Sciences Soars 141% on Truly Impressive Pivotal Wet AMD Trial Win (TIKR)
10:14AM	This Biotech Company Added Nearly $3B To Its Market Cap Heres Why KOD Stock Is Ripping Today (Stocktwits)
09:16AM	Kodiak Sciences stock soars on positive AMD trial data (Investing.com)
07:31AM	Kodiak Sciences Stock Pops 64% After Eye-Disease Drugs Pass Key Trial (Barrons.com)
07:02AM	Loading…
07:02AM	Kodiak Sciences Shares Rise After DAYBREAK Phase 3 Trial Results (InvestorsHub)
06:30AM	Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-week Dosing Interval Using Strict Treat-to-Dryness Real World Retreatment Criteria. (PR Newswire)
Sep-25-26 06:01PM	Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration (PR Newswire)
Aug-13-26 04:00PM	Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results (PR Newswire) -7.90%
Aug-10-26 04:43PM	Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema (PR Newswire)
Aug-06-26 07:00AM	Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026 (PR Newswire)
May-28-26 06:09PM	Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference (PR Newswire)
May-07-26 04:00PM	Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results (PR Newswire) -6.11%
May-01-26 12:23AM	Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences (PR Newswire)
Mar-31-26 04:45PM	Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results (PR Newswire) +13.25% +12.30%
Mar-27-26 08:23AM	How Kodiak Sciences Stock Rises To $120? (Trefis) -6.94%
Mar-26-26 06:46AM	Wave crashes on obesity drug update; Kodiaks reboot pays dividends (BioPharma Dive) +74.77%
06:00AM	Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda (tarcocimab tedromer) Over Sham (PR Newswire)
Feb-06-26 11:31AM	KOD Stock Up 24% in 3 Months: Here's What You Need to Know (Zacks) +9.66%
Feb-04-26 07:00AM	Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026 (PR Newswire) -6.87%
08:19PM	Loading…
Jan-07-26 08:19PM	Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference (PR Newswire) +8.06%
Dec-30-25 08:45AM	The Biggest IPO of the Year Prompts Huge Insider Buy (24/7 Wall St.)
Dec-22-25 10:11AM	What Awaits These 4 Biotech Stocks That More Than Doubled in 2025 (Zacks) +10.04%
Dec-18-25 08:26PM	Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Dec-16-25 10:55PM	Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock (PR Newswire) +11.77%
Dec-15-25 04:01PM	Kodiak Sciences Announces Proposed Public Offering of Common Stock (PR Newswire)
Nov-14-25 07:36AM	Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus (Zacks)
Nov-13-25 04:05PM	Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results (PR Newswire) -6.81%
Nov-12-25 05:48PM	Kodiak Sciences to Present at Upcoming Investor Conferences (PR Newswire)
Nov-05-25 07:00AM	Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (=90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI) (PR Newswire)
Sep-15-25 07:00AM	New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI) (PR Newswire)
Sep-12-25 11:30AM	Why Is Kodiak Sciences (KOD) Down 1.2% Since Last Earnings Report? (Zacks) -6.75%
Sep-02-25 08:00AM	Kodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflammation (MESI) (PR Newswire)
Aug-29-25 03:05PM	Jim Cramer on Kodiak Sciences: "That's a Pure Spec Stock" (Insider Monkey)
Aug-26-25 07:52PM	Lightning Round: Oklo goes up every time there's a good headline, buy Oklo, says Jim Cramer (CNBC TV)
Aug-19-25 02:18PM	Kodiak Sciences to Present at American Chemical Society Fall 2025 (PR Newswire) -15.73%
Aug-14-25 11:41AM	Kodiak Q2 Loss Wider Than Expected, Pipeline Development in Focus (Zacks) +16.47%
Aug-13-25 04:00PM	Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results (PR Newswire)
Jul-10-25 08:00AM	Kodiak Sciences to Host Investor R&D Day on July 16, 2025 (PR Newswire)
Jun-25-25 04:45PM	Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society (PR Newswire)
Jun-24-25 05:51AM	Age-Related Vision Dysfunction Market Research 2025-2035 \| Kodiak Sciences, Genentech, and AbbVie Drive Innovations Through Advanced, Sustainable Solutions (GlobeNewswire)
Jun-13-25 11:30AM	Why Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report? (Zacks) +5.43%
May-29-25 09:32PM	Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference (PR Newswire)
May-15-25 11:04AM	Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus (Zacks) -15.48%
May-14-25 04:15PM	Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results (PR Newswire)
May-01-25 11:43PM	Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases (PR Newswire) +6.90%
Apr-01-25 09:35AM	Down -28.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Kodiak Sciences (KOD) (Zacks) -8.73%
Mar-28-25 09:45AM	Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
Mar-27-25 04:01PM	Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Mar-26-25 03:58PM	Is Kodiak Sciences Inc. (KOD) The Hot Biotech Stock Under $5? (InsiderMonkey) -6.08%
Mar-10-25 04:39PM	Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy (PR Newswire)
Feb-04-25 07:30AM	Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025 (PR Newswire)
Jan-13-25 04:26PM	Heres Why Kodiak Sciences Inc. (KOD) Is Skyrocketing (Insider Monkey) -6.13%
Jan-07-25 06:00AM	Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-09-24 09:18PM	Nona Biosciences and Kodiak Sciences Partner on Next-Generation Antibody Therapies for Ophthalmic Diseases (PR Newswire) +29.63%
12:33PM	Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock (Benzinga)
Nov-25-24 09:55AM	Kodiak Sciences Inc. (KOD) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
Nov-14-24 04:01PM	Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results (PR Newswire)
Nov-11-24 06:15AM	Kodiak Sciences to Participate in Upcoming Investor Conferences (PR Newswire) +8.54%
Oct-14-24 05:35PM	Kodiak Sciences to Present at Innovate Retina 2024 (PR Newswire)
Sep-23-24 06:00AM	Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time (PR Newswire)
Sep-17-24 04:05PM	Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City (PR Newswire)
Sep-13-24 11:30AM	Why Is Kodiak Sciences (KOD) Down 8.1% Since Last Earnings Report? (Zacks) +13.87%
Aug-16-24 10:42AM	Kodiak (KOD) Q2 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
Aug-14-24 09:54PM	KOD Stock Earnings: Kodiak Sciences Beats EPS for Q2 2024 (InvestorPlace)
04:01PM	Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results (PR Newswire)
Jul-10-24 12:00PM	All You Need to Know About Kodiak Sciences (KOD) Rating Upgrade to Buy (Zacks)
Jun-20-24 08:23AM	Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio? (Zacks)
Jun-14-24 11:30AM	Why Is Kodiak Sciences (KOD) Down 26.2% Since Last Earnings Report? (Zacks)
May-29-24 04:36PM	Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences (PR Newswire)
May-16-24 12:51PM	Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
May-15-24 10:55PM	KOD Stock Earnings: Kodiak Sciences Beats EPS for Q1 2024 (InvestorPlace)
04:01PM	Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results (PR Newswire)
May-14-24 07:31AM	Kodiak Sciences dosing subjects in Phase III trial of diabetic retinopathy drug (Clinical Trials Arena)
May-13-24 07:32PM	Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy (PR Newswire) +6.09%
May-02-24 04:30PM	Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform (PR Newswire)
Apr-04-24 12:09PM	Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks (Zacks)
Apr-01-24 05:04PM	Kodiak Sciences Inc. (NASDAQ:KOD) Q4 2023 Earnings Call Transcript (Insider Monkey) -15.40%
12:00PM	Kodiak (KOD) Stock Falls on Q4 Earnings Miss, Pipeline in Focus (Zacks)
Mar-29-24 10:36AM	Q4 2023 Kodiak Sciences Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-28-24 11:53AM	KOD Stock Earnings: Kodiak Sciences Misses EPS for Q4 2023 (InvestorPlace) -29.40%
08:32AM	Kodiak Sciences Inc (KOD) Posts Q4 and Full Year 2023 Financial Results (GuruFocus.com)
06:30AM	Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
Mar-26-24 06:15AM	Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024 (PR Newswire) +16.01%
Jan-30-24 06:30AM	Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting (PR Newswire) -8.58%
Jan-04-24 04:15PM	Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-14-23 11:30AM	Kodiak Sciences Inc. (KOD) Up 43.6% Since Last Earnings Report: Can It Continue? (Zacks) +6.21%
Nov-21-23 04:15PM	Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference (PR Newswire) -7.41% +6.67%
Nov-15-23 08:00AM	Kodiak (KOD) Beats Q3 Earnings, Provides Pipeline Updates (Zacks) +5.21%
Nov-14-23 06:09PM	Kodiak Sciences Inc (KOD) Reports Q3 2023 Financial Results: Net Loss Narrows, R&D Expenses ... (GuruFocus.com) +6.67%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BORGESON JOHN A.	Chief Financial Officer	Oct 21 '26	Option Exercise	2.49	30,000	74,700	241,930	Oct 23 05:00 PM
BORGESON JOHN A.	Chief Financial Officer	Oct 21 '26	Sale	90.01	30,000	2,700,322	211,930	Oct 23 05:00 PM
JOHN BORGESON	Officer	Oct 21 '26	Proposed Sale	92.97	30,000	2,789,100		Oct 21 04:21 PM
BAKER BROS. ADVISORS LP	Director	Sep 28 '26	Buy	88.77	681,866	60,529,354	20,159,386	Sep 30 04:31 PM
BAKER BROS. ADVISORS LP	Director	Sep 29 '26	Buy	85.05	33,726	2,868,255	20,191,214	Sep 30 04:31 PM
BAKER BROS. ADVISORS LP	Director	Sep 28 '26	Buy	83.58	418,323	34,963,077	19,515,907	Sep 30 04:30 PM
BAKER BROS. ADVISORS LP	Director	Sep 28 '26	Buy	72.57	807,840	58,625,708	19,121,134	Sep 30 04:29 PM
PERLROTH VICTOR	Chairman and CEO	Sep 25 '26	Option Exercise	4.20	1,280,524	5,381,943	3,676,062	Sep 29 07:44 PM
BORGESON JOHN A.	Chief Financial Officer	Jun 04 '26	Option Exercise	1.04	30,000	31,200	241,930	Jun 05 05:56 PM
BORGESON JOHN A.	Chief Financial Officer	Jun 04 '26	Sale	34.10	30,000	1,023,009	211,930	Jun 05 05:56 PM
JOHN BORGESON	Officer	Jun 04 '26	Proposed Sale	33.87	30,000	1,016,100		Jun 04 04:29 PM
BORGESON JOHN A.	Chief Financial Officer	Apr 15 '26	Option Exercise	1.04	28,614	29,759	211,930	Apr 16 05:00 PM
BORGESON JOHN A.	Chief Financial Officer	Apr 02 '26	Option Exercise	1.04	30,000	31,200	213,316	Apr 02 08:26 PM
BORGESON JOHN A.	Chief Financial Officer	Apr 02 '26	Sale	39.92	30,000	1,197,488	183,316	Apr 02 08:26 PM
JOHN BORGESON	Officer	Apr 02 '26	Proposed Sale	42.81	30,000	1,284,300		Apr 02 04:23 PM
PERLROTH VICTOR	Chairman and CEO	Mar 25 '26	Option Exercise	1.04	300,000	312,000	2,395,538	Mar 27 06:08 PM
BAKER BROS. ADVISORS LP	Director	Dec 18 '25	Buy	23.00	2,608,696	60,000,008	18,358,772	Dec 19 04:06 PM

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Co-FounderDr. Victor Perlroth M.D.

M.B.A.Mr. John A. Borgeson CPA

Chief Technology OfficerMr. Wayne To M.Phil.

M.P.H.Dr. Dolly S. Chang M.D.

Senior Vice President of DevelopmentDr. Hong Liang Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KOD

Kodiak Sciences Inc

Upgrade your Finviz experience